Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02655822
Title Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Corvus Pharmaceuticals, Inc.

renal cell carcinoma

prostate adenocarcinoma


Atezolizumab + CPI-444


Age Groups: senior | adult
Covered Countries USA | CAN

No variant requirements are available.